Search:

Login | Subscribe

Home > Companies > Allergy Therapeutics

Price	Market	Sector	Market Cap
10.00p (0.00p) 0.00%	AIM	Medicine and Biotech Research	£8.2m

Add to company folder | Print

Related Companies

APH	4.62p	0.00%
CBF	2.00p	-11.11%
CRX	2.75p	0.00%
EVC	25.75p	0.00%
FUL	3.12p	0.00%
FUM	28.25p	-2.59%
GMX	1.75p	0.00%
GWP	30.00p	0.00%
HML	0.42p	0.00%
MMG	7.25p	0.00%
MPM	14.25p	0.00%
OMH	3.50p	0.00%
PLE	16.50p	0.00%
PRM	20.50p	-8.89%
PRX	145.00p	5.46%
RNSM	7.75p	0.00%
RCG	35.00p	-6.67%
RGT	6.50p	0.00%

Commentary

Pharmaceutical developer focused on allergy vaccines

Recent Articles

Allergy group in ‘breakthrough’	14/05/2008
Stockpicking with the experts	01/06/2007
Big tests for Allergy Therapeutics	19/05/2006
Runners and riders in the medical stakes	10/04/2006
Aero Inventory soars	16/09/2005
Allergy Therapeutics	14/09/2005
Healthy demand for drug developers	30/03/2005
Allergy Therapeutics – not to be sneezed at	01/02/2005

Recent Announcements

AGM Statement	20/11/2008
Holding(s) in Company	13/11/2008
Annual Report and Accounts	28/10/2008
Holding(s) in Company	29/09/2008
Final Results	22/09/2008
Research Update	22/09/2008
Holding(s) in Company	22/08/2008
Research Update	09/06/2008
Research Update	14/05/2008
Director/PDMR Shareholding	07/05/2008
More

Articles from the Sector

Stroke hope at ReNeuron	28/11/2008
Futura Medical	28/11/2008
Option deal boosts ImmuPharma	25/11/2008
Digital imager targets AIM	24/11/2008
Vectura loses interim £11.7m	24/11/2008
GW trims loss	19/11/2008
Asterand	18/11/2008
EU trial cheers Plethora	07/11/2008
IS Pharma	05/11/2008
Animalcare nurturing high-margin growth	03/11/2008
More

Financial History

Financial Year End	30/06/2004	30/06/2005	30/06/2006	30/06/2007	30/06/2008
Currency	GBP	GBP	GBP	GBP	GBP
Turnover	18.00	20.61	23.56	25.74	31.02
Operating Profit	1.56	-2.42	-6.71	-26.27	-15.59
Pretax Profit	1.59	-1.93	-6.17	-25.76	-20.24
Earnings After Tax	1.22	-1.93	-6.17	-23.26	-20.30
Profit Available For Dividend	0.00	0.00	0.00	0.00	0.00
Ordinary Dividends	0.00	0.00	0.00	0.00	0.00
Retained Profit	1.22	0.00	-6.17	0.00	0.00
Shareholders Funds	7.08	20.08	32.70	8.60	-11.29
Net Current Assets	2.29	14.86	26.15	0.00	0.00
Adjusted Earnings Per Share Undiluted	0.00	0.00	0.00	-28.40	-24.80
Adj Earnings Per Share	0.00	0.00	0.00	-28.40	-24.80
Dividend Per Share	0.00	0.00	0.00	0.00	0.00

Chart

Click here for interactive charting

Company Details
Address	Dominion Way, Worthing, BN14 8SA
Telephone	01903 844 700
Fax	01903 844 744
Executives
Chairman	Ignace Goethals (2.30% holding)
Chief Executive	Keith Carter (3.90% holding)
Finance Director	Ian Postlethwaite (0.00% holding)
Marketing Director	Christian Graetz (0.50% holding)
Main Shareholders
	Smithkline Beecham Biologicals Manufacturing S.A: 16.1% Fidelity: 11.9% OTC Ltd: 9.4% AXA S.A.: 7.1%
Advisers
Nominated Adviser	Nomura
Nominated Broker	Teathers; Nomura
Solicitors	Ashurst
Auditors	Grant Thornton
Registrar	Capita Registrars

Commentary
Pharmaceutical developer focused on allergy vaccines
Company Data
Code	AGY
Sedol	GB00B02LCQ
Shares In Issue	81.951 m
Indices
Entry on AIM	11/10/2004
Interim Results	Mar
Final Results	Sep
Year End	Jun
Accounts Due	Oct
Int div payment	n/a
Fin div payment	n/a
Int net div per share	nil
Fin net div per share	nil
Probable CGT relief	Yes